Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Avidity Biosciences, Inc. Director's Dealing 2024

Dec 20, 2024

30894_dirs_2024-12-19_2e5afc43-dc3b-4fca-a310-9e336ee965e0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2024-12-18

Reporting Person: McCarthy Teresa (Chief Human Resources Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-12-18 Common Stock S 11151 $32.66 Disposed 82867 Direct

Footnotes

F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 25,000 time-based restricted stock units (RSUs) that vested on December 17, 2024. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on June 17, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.66 to $32.66. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.